Express Scripts Takes Legal Action Against FTC Over Drug Pricing Allegations

Tuesday, 17 September 2024, 12:45

Express Scripts is suing the FTC over a drug pricing report. The suit claims the FTC’s July 2024 report includes false information about the PBM industry. Express Scripts demands a retraction of the report, claiming significant inaccuracies. This high-profile case may set a precedent for future regulatory evaluations in the pharmaceutical sector.
LivaRava_Finance_Default_1.png
Express Scripts Takes Legal Action Against FTC Over Drug Pricing Allegations

Legal Action Initiated by Express Scripts

In a significant move, Express Scripts, a prominent pharmacy benefit manager (PBM), has filed a lawsuit against the FTC over claims made in its drug pricing report published in July 2024. The report, according to Express Scripts, is riddled with false and misleading claims regarding the PBM industry.

Claims of Inaccuracies

Express Scripts argues that the allegations presented by the FTC misrepresent the realities of the PBM market, accusing the agency of disseminating misleading information that could adversely affect their reputation. The lawsuit demands a full retraction of the report to rectify these purported inaccuracies.

Potential Implications

This lawsuit could have far-reaching implications, not just for Express Scripts but for the entire pharmaceutical industry, especially in terms of how regulatory agencies prepare and present their findings.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe